HC Wainwright Predicts Upstream Bio Q2 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – HC Wainwright issued their Q2 2026 EPS estimates for shares of Upstream Bio in a report issued on Wednesday, June 3rd. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.76) for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Upstream Bio’s Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($3.09) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($3.35) EPS and FY2030 earnings at ($3.42) EPS.

Several other equities research analysts have also recently issued reports on UPB. Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Mizuho decreased their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price on the stock. in a research report on Friday, March 27th. Finally, Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $38.20.

Upstream Bio Price Performance

Upstream Bio stock opened at $7.43 on Friday. Upstream Bio has a 12-month low of $7.18 and a 12-month high of $33.68. The stock has a market capitalization of $404.34 million, a P/E ratio of -2.55 and a beta of 1.10. The firm’s 50-day moving average is $9.10 and its two-hundred day moving average is $17.57.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.03 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of UPB. AQR Capital Management LLC purchased a new position in Upstream Bio in the first quarter valued at approximately $115,000. Woodline Partners LP raised its holdings in Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after buying an additional 30,552 shares during the period. Creative Planning purchased a new position in Upstream Bio in the second quarter valued at approximately $154,000. JPMorgan Chase & Co. raised its holdings in Upstream Bio by 8.4% in the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after buying an additional 1,275 shares during the period. Finally, Legal & General Group Plc raised its holdings in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.